Description

Nivolumab is a monoclonal antibody used in cancer immunotherapy. It works by blocking the programmed cell death protein 1 (PD-1) pathway, enhancing the immune response against tumor cells.

Interpreter Notes

Interpreters should be aware that 'Nivolumab' is often used in oncology contexts, particularly in discussions about immunotherapy treatments. There are no common colloquial variants, but interpreters should ensure they maintain a formal register when discussing this medication to avoid confusion with other cancer treatments.

Example Sentences

EN: The oncologist recommended Nivolumab as a treatment option for the patient.

ES: El oncólogo recomendó Nivolumab como una opción de tratamiento para el paciente.

Common Interpreter Mistakes

Confusing Nivolumab with similar-sounding medications; misinterpreting the context of immunotherapy; using informal language when discussing treatment options.